These results provide longer-term evidence that Scemblix demonstrated increasingly superior molecular responses at week 144 compared with established tyrosine kinase inhibitors (TKIs), strengthening ...

Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...

The ODT formulation utilizes proprietary technology to improve solubility and dissolution rates, maintaining bioavailability even when taken concomitantly with acid-reducing therapies. The Food and ...

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. In this type of cancer, the bone marrow produces too many white blood cells. If the disease isn’t effectively treated, it ...

During CML treatment, it’s important to get enough nutrients by eating foods like protein, whole grains, fruits, and vegetables, which can help manage side effects and support your body. If you have ...

Articles published in this focus collection were selected from recent issues of Leukemia. They highlight new developments in our understanding and management of persons with CML. CML was the first ...

Novartis’ Scemblix continued to show superior efficacy and favourable safety and tolerability profile at week 144 in newly diagnosed CML: Basel Wednesday, June 3, 2026, 13:00 Hr ...